1 |
O'Regan KN, Nishino M, Armand P, Kelly PJ, Hwang DG, Di Salvo D. Sonographic features of pectoralis muscle necrosis secondary to gemcitabine-induced radiation recall: case report and review of current literature. J Ultrasound Med 2010;29:1499-502.
DOI
|
2 |
Matthews RH, Kadoch C, Ercal N. Alcohol as a potential contributing factor in radiation complications. Clin Adv Hematol Oncol 2009;7:257-62.
|
3 |
Reed GB Jr, Cox AJ Jr. The human liver after radiation injury: a form of veno-occlusive disease. Am J Pathol. 1966;48:597-611.
|
4 |
Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006;24:5313-27.
DOI
|
5 |
Steinberg W. The clinical utility of the CA 19-9 tumorassociated antigen. Am J Gastroenterol 1990;85:350-5.
|
6 |
Lamerz R. Role of tumour markers, cytogenetics. Ann Oncol 1999;10 Suppl 4:145-9.
DOI
|
7 |
Pearce S, Thornes H, Carr D, Tanner A. Diagnostic pitfall; interpretation of CA 19-9 concentrations in the presence of hepatic dysfunction. Gut 1994;35:707-8.
DOI
|
8 |
Marks LB, Yorke ED, Jackson A, et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys 2010;76(3 Suppl):S10-9.
DOI
|
9 |
National Cancer Institute, Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 [Internet]. Bethesda, MD: National Cancer Institute; c2016 [cited 2016 Jun 7]. Available from: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm.
|
10 |
Mann DV, Edwards R, Ho S, Lau WY, Glazer G. Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice. Eur J Surg Oncol 2000;26:474-9.
DOI
|
11 |
Maestranzi S, Przemioslo R, Mitchell H, Sherwood RA. The effect of benign and malignant liver disease on the tumour markers CA19-9 and CEA. Ann Clin Biochem 1998;35(Pt 1):99-103.
DOI
|
12 |
Pines E, Slama JL, Holeman A, Ley G, Malbec D, Boudon P. Unusually high level of CA 19-9 in chronic pancreatitis. Gastroenterol Clin Biol 1995;19:641-2.
|
13 |
Safi F, Roscher R, Beger HG. The clinical relevance of the tumor marker CA 19-9 in the diagnosing and monitoring of pancreatic carcinoma. Bull Cancer 1990;77:83-91.
|
14 |
Petit JM, Vaillant G, Olsson NO, et al. Elevated serum CA19-9 levels in poorly controlled diabetic patients: relationship with Lewis blood group. Gastroenterol Clin Biol 1994;18:17-20.
|
15 |
Kodama T, Satoh H, Ishikawa H, Ohtsuka M. Serum levels of CA19-9 in patients with nonmalignant respiratory diseases. J Clin Lab Anal 2007;21:103-6.
DOI
|
16 |
Camidge R, Price A. Characterizing the phenomenon of radiation recall dermatitis. Radiother Oncol 2001;59:237-45.
DOI
|
17 |
Azria D, Magne N, Zouhair A, et al. Radiation recall: a well recognized but neglected phenomenon. Cancer Treat Rev 2005;31:555-70.
DOI
|
18 |
Friedlander PA, Bansal R, Schwartz L, Wagman R, Posner J, Kemeny N. Gemcitabine-related radiation recall preferentially involves internal tissue and organs. Cancer 2004;100:1793-9.
DOI
|
19 |
Jeter MD, Janne PA, Brooks S, et al. Gemcitabine-induced radiation recall. Int J Radiat Oncol Biol Phys 2002;53:394-400.
DOI
|
20 |
Ganem G, Solal-Celigny P, Joffroy A, Tassy D, Delpon A, Dupuis O. Radiation myositis: the possible role of gemcitabine. Ann Oncol 2000;11:1615-6.
DOI
|